138 related articles for article (PubMed ID: 3595383)
1. Drug disposition in patients with HBsAg-positive chronic liver disease.
Villeneuve JP; Thibeault MJ; Ampelas M; Fortunet-Fouin H; LaMarre L; Côté J; Pomier-Layrargues G; Huet PM
Dig Dis Sci; 1987 Jul; 32(7):710-4. PubMed ID: 3595383
[TBL] [Abstract][Full Text] [Related]
2. Effect of portacaval shunt on drug disposition in patients with cirrhosis.
Pomier-Layrargues G; Huet PM; Villeneuve JP; Marleau D
Gastroenterology; 1986 Jul; 91(1):163-7. PubMed ID: 3710065
[TBL] [Abstract][Full Text] [Related]
3. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.
Huet PM; Lelorier J
Clin Pharmacol Ther; 1980 Aug; 28(2):208-15. PubMed ID: 7398188
[TBL] [Abstract][Full Text] [Related]
4. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
[TBL] [Abstract][Full Text] [Related]
5. The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.
Lay CS; Tsai YT; Kong CW; Lee FY; Chang TT; Lin HC; Yang CM; Lee SD; Chiang BN; Lo KJ
Clin Pharmacol Ther; 1988 Oct; 44(4):453-7. PubMed ID: 3168396
[TBL] [Abstract][Full Text] [Related]
6. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
Hepner GW; Vesell ES; Lipton A; Harvey HA; Wilkinson GR; Schenker S
J Lab Clin Med; 1977 Sep; 90(3):440-56. PubMed ID: 894100
[No Abstract] [Full Text] [Related]
7. Circulating immune complexes in chronic hepatitis as related to the presence of HBsAg.
Radu D; Dumitraşcu D; Părău N; Urcan S; Stanciu L; Tăpălagă D; Ban A; Dumitraşcu D; Rusu C
Med Interne; 1984; 22(1):61-5. PubMed ID: 6710050
[TBL] [Abstract][Full Text] [Related]
8. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.
Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
Clin Pharmacol Ther; 1976 Sep; 20(3):290-9. PubMed ID: 954351
[TBL] [Abstract][Full Text] [Related]
9. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
[TBL] [Abstract][Full Text] [Related]
10. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity.
Herold C; Heinz R; Radespiel-Tröger M; Schneider HT; Schuppan D; Hahn EG
Liver; 2001 Feb; 21(1):26-30. PubMed ID: 11169069
[TBL] [Abstract][Full Text] [Related]
11. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
Testa R; Caglieris S; Risso D; Arzani L; Campo N; Alvarez S; Giannini E; Lantieri PB; Celle G
Am J Gastroenterol; 1997 Dec; 92(12):2268-73. PubMed ID: 9399768
[TBL] [Abstract][Full Text] [Related]
12. A simple method for routine determination of the metabolic liver capacity: the aminopyrine breath test.
Haustein KO; Schenker E
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):190-6. PubMed ID: 3922902
[TBL] [Abstract][Full Text] [Related]
13. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
[TBL] [Abstract][Full Text] [Related]
14. [Antibodies against hepatitis B virus in chronic non-alcoholic HBsAg-negative hepatopathies].
Moreira Vicente VF; Simón Marco MA; Pascasio Acevedo JM; Ruiz del Arbol Olmos L; Larraona Moreno JL; González Martín JA; Aguilera Musso D; Barcena Marugan R; Bueno Vallejo R
Med Clin (Barc); 1984 Mar; 82(12):522-30. PubMed ID: 6738151
[No Abstract] [Full Text] [Related]
15. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
Fasoli A; Giannini E; Botta F; Romagnoli P; Risso D; Celle G; Testa R
Hepatogastroenterology; 2000; 47(31):234-8. PubMed ID: 10690614
[TBL] [Abstract][Full Text] [Related]
16. HBsAg clearance in patients with long-standing chronic active hepatitis B and hepatitis B virus-induced liver cirrhosis.
Poralla T; Manns M; Hütteroth TH; Hess G; Dormeyer HH; Meyer zum Büschenfelde KH
Digestion; 1986; 33(1):53-60. PubMed ID: 3940237
[TBL] [Abstract][Full Text] [Related]
17. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
Testa R; Campo N; Caglieris S; Risso D; Alvarez S; Arzani L; Giannini E; Lantieri PB; Celle G
Hepatogastroenterology; 1998; 45(19):154-9. PubMed ID: 9496506
[TBL] [Abstract][Full Text] [Related]
18. The aminopyrine breath test does not correlate with histologic disease severity in patients with cholestasis.
Baker AL; Krager PS; Kotake AN; Schoeller DA
Hepatology; 1987; 7(3):464-7. PubMed ID: 3570158
[TBL] [Abstract][Full Text] [Related]
19. [Drug metabolism in patients with liver disease (author's transl)].
Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of the surface antigen of the hepatitis type B virus (HBsAg) in chronic hepatic disease].
Ocaña Andrade E; Valverde Castañeda N; Garrido Palma J; Carrillo Cambero JL
Rev Gastroenterol Mex; 1985; 50(1):19-22. PubMed ID: 4089439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
